Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109161 · ClinicalTrials.gov registry record · Phase 2
Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
A Phase 2 study of Multiple Sclerosis, sponsored by PDL BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT00109161: Completed Phase 2 study of Multiple Sclerosis, sponsored by PDL BioPharma.
NCT00109161 is a Phase 2 study of Multiple Sclerosis that has completed, run by PDL BioPharma. The registered enrollment target is 270 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00109161, a Phase 2 study of Multiple Sclerosis, has completed, sponsored by PDL BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research study is being conducted in the U.S. and Europe to evaluate the safety and efficacy of daclizumab for the treatment of multiple sclerosis (MS).
Conditions Studied
Interventions
- DRUG Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
Study Locations (20)
New York
- Upstate Clinical Research - Albany
- Albany Medical Center - Albany
- Winthrop University Hospital - Mineola
- Hospital for Joint Diseases, MS Care Center - New York
- University of Rochester Medical Center - Rochester
Michigan
- Wayne State University MS Center - Detroit
- Michigan State University - East Lansing
- Michigan Medical P.C. Neurology - Grand Rapids
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
- Mayo Clinic - Scottsdale
California
- Sutter East Bay Medical Foundation - Berkeley
Florida
- Neurology Associates, P.A. - Maitland
Georgia
- The Multiple Sclerosis Center of Atlanta - Atlanta
Illinois
- Consultants in Neurology - Northbrook
Kansas
- KUMC Neurology - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
What the finished NCT00109161 record still lists
NCT00109161 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Daclizumab (Anti-CD25 Humanized Monoclonal Antibody) is the first listed.
NCT00109161 names 20 study sites across 13 states, led by New York, Michigan, Arizona.
Frequently Asked Questions
What is clinical trial NCT00109161 about?
NCT00109161 is a clinical study titled "Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis". This research study is being conducted in the U.S. and Europe to evaluate the safety and efficacy of daclizumab for the treatment of multiple sclerosis (MS).
What is the current status of trial NCT00109161?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2005-04. Estimated completion is 2006-10.
What conditions does trial NCT00109161 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT00109161?
The interventions under investigation include: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody) (DRUG).
Who is sponsoring clinical trial NCT00109161?
This trial is sponsored by PDL BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00109161 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00109161's enrollment target sits among peer trials
270 65th of 315 higher than 251 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RECRUITING · Phase 2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia